Belantamab Mafodotin vs. DaratumumabBelantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Sponsor:

PrECOG, LLC.

Code:

NCT07285239

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Arm A: Belantamab Mafodotin

Arm B: Daratumumab Hyaluronidase

Bortezomib

Lenalidomide

Dexamethasone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-01. This information was provided to ClinicalTrials.gov by PrECOG, LLC. on 2026-08-17.